Glucagon-like peptide-1: difference between revisions
Diff·revision 25 → 26·17:34, 18 Oct 2024
Difference between revision 25 and revision 26 of Glucagon-like peptide-1. 1 line changed; the page grew by 178 bytes.
| Revision 25 — 00:10, 12 Oct 2024 HalfLifeHavel (talk) correct percentage: source reports placebo-adjusted 7,221 bytes ±0 | Revision 26 — 17:34, 18 Oct 2024 EmptyingElke (talk) move table to the section it supports 7,399 bytes +178 | ||
|---|---|---|---|
| 12 | | Sequence position = Proglucagon 78–107 | 12 | | Sequence position = Proglucagon 78–107 |
| 13 | }} | 13 | }} |
| + | 14 | {{hatnote|This article is about the endogenous hormone. For the drug class that mimics it, see [[GLP-1 receptor agonist]]. For the receptor it acts on, see [[GLP-1 receptor]].}} | |
| 14 | 15 | ||
| 15 | '''Glucagon-like peptide-1''' ('''GLP-1''') is a 30- or 31-residue [[peptide]] hormone released from [[Enteroendocrine L cell|enteroendocrine L cells]] of the distal small intestine and colon in response to nutrient ingestion. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucose-dependent insulinotropic polypeptide]] (GIP).{{r|holst2007}} | 16 | '''Glucagon-like peptide-1''' ('''GLP-1''') is a 30- or 31-residue [[peptide]] hormone released from [[Enteroendocrine L cell|enteroendocrine L cells]] of the distal small intestine and colon in response to nutrient ingestion. It is one of the two principal [[Incretin effect|incretin]] hormones, the other being [[Glucose-dependent insulinotropic polypeptide]] (GIP).{{r|holst2007}} |